150 likes | 305 Views
"Cystic Fibrosis - Pipeline Review, H2 2014"report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.
E N D
Category : Pharmaceuticals & Healthcare Cystic Fibrosis - Pipeline Review, H2 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/63083/cystic-fibrosis-pipeline-review
Summary Global Markets Direct’s, ‘Cystic Fibrosis - Pipeline Review, H2 2014’, provides an overview of the Cystic Fibrosis’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Cystic Fibrosis Overview 11Therapeutics Development 12Pipeline Products for Cystic Fibrosis - Overview 12Pipeline Products for Cystic Fibrosis - Comparative Analysis 13Cystic Fibrosis - Therapeutics under Development by Companies 14Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 18Cystic Fibrosis - Pipeline Products Glance 20Late Stage Products 20Clinical Stage Products 21Early Stage Products 22
Table of Content Unknown Stage Products 23Cystic Fibrosis - Products under Development by Companies 24Cystic Fibrosis - Products under Investigation by Universities/Institutes 29Cystic Fibrosis - Companies Involved in Therapeutics Development 30Alaxia SAS 30AlgiPharma AS 31Bayer AG 32Beech Tree Labs, Inc. 33Carolus Therapeutics, Inc. 34Celsus Therapeutics Plc 35Celtaxsys, Inc. 36Chiesi Farmaceutici SpA 37Cilian AG 38Concert Pharmaceuticals, Inc. 39Corbus pharmaceuticals, Inc. 40
List Of Tables Number of Products under Development for Cystic Fibrosis, H2 2014 18Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 20Number of Products under Development by Companies, H2 2014 (Contd..2) 22Number of Products under Development by Companies, H2 2014 (Contd..3) 23Number of Products under Investigation by Universities/Institutes, H2 2014 25Comparative Analysis by Late Stage Development, H2 2014 26Comparative Analysis by Clinical Stage Development, H2 2014 27Comparative Analysis by Early Stage Development, H2 2014 28Comparative Analysis by Unknown Stage Development, H2 2014 29Products under Development by Companies, H2 2014 30Products under Development by Companies, H2 2014 (Contd..1) 31
List Of Tables Products under Development by Companies, H2 2014 (Contd..2) 32Products under Development by Companies, H2 2014 (Contd..3) 33Products under Development by Companies, H2 2014 (Contd..4) 34Products under Investigation by Universities/Institutes, H2 2014 35Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2014 36Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2014 37Cystic Fibrosis - Pipeline by Bayer AG, H2 2014 38Cystic Fibrosis - Pipeline by Beech Tree Labs, Inc., H2 2014 39Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2014 40Cystic Fibrosis - Pipeline by Celsus Therapeutics Plc, H2 2014 41Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2014 42Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2014 43Cystic Fibrosis - Pipeline by Cilian AG, H2 2014 44 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H2 2014 Cystic Fibrosis - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2014 48
List of Figures Number of Products under Development for Cystic Fibrosis, H2 2014 18Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 20Number of Products under Investigation by Universities/Institutes, H2 2014 24Comparative Analysis by Late Stage Development, H2 2014 26Comparative Analysis by Clinical Stage Development, H2 2014 27Comparative Analysis by Early Stage Products, H2 2014 28Assessment by Monotherapy Products, H2 2014 86Number of Products by Top 10 Targets, H2 2014 88Number of Products by Stage and Top 10 Targets, H2 2014 88Number of Products by Top 10 Mechanism of Actions, H2 2014 91Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 91Number of Products by Top 10 Routes of Administration, H2 2014 94
Related Reports • Global Neurosurgery Market 2015-2019 • BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review • Ampio Pharmaceuticals, Inc. (AMPE) - Financial and Strategic SWOT Analysis Review • MiMedx Group, Inc (MDXG) - Financial and Strategic SWOT Analysis Review • Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review
Related Reports • MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review • Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review • RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review • Pharmaceuticals & Healthcare Market Research Reports
Cystic Fibrosis - Pipeline Review, H2 2014 Published: Oct 2014 | 267 Pages Cystic Fibrosis - Pipeline Review, H2 2014 report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Price
Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news